NASDAQ: MIRAMira Pharmaceuticals Inc Stock
$4.65-0.14 (-2.92%)
Updated Sep 29, 2023
MIRA Price
$4.65
Fair Value Price
N/A
Market Cap
$68.73M
52 Week Low
$3.00
52 Week High
$7.98
P/E
N/A
P/B
57.44x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.2
Operating Cash Flow
N/A
Beta
0.43
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MIRA Overview
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MIRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MIRA is poor value based on its book value relative to its share price (57.44x), compared to the US Biotechnology industry average (5.09x)
P/B vs Industry Valuation
MIRA's short-term liabilities ($2.58M) exceed its short-term assets ($420.72k)
Short-term Liabilities Financials
MIRA's short-term assets ($420.72k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more MIRA due diligence checks available for Premium users.
Be the first to know about important MIRA news, forecast changes, insider trades & much more!
MIRA News
Valuation
MIRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
57.44x
Industry
5.09x
MIRA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MIRA's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.3M
Profit Margin
0%
Assets to liabilities
Assets
$3.8M
Liabilities
$2.6M
Debt to equity
2.2
MIRA's short-term liabilities ($2.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MIRA's short-term assets ($420.72k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MIRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$660.8k
Investing
$0.0
Financing
$684.3k
MIRA vs Biotech Stocks
Mira Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.